What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
President Donald Trump’s April 18, 2026, executive order directs federal agencies to accelerate research and potential regulatory review of psychedelic drugs for serious mental illness. It did not approve a treatment, establish that any candidate works, or make psychedelic therapies generally available. “MAHA-backed” describes the political context around the initiative—not a formal program name in the order.
What did Trump’s psychedelic research order do?
Executive Order 14401, “Accelerating Medical Treatments for Serious Mental Illness,” sets a federal policy of speeding research models and appropriate drug approvals for psychedelic drugs that may help address serious mental illness. It directs agencies to support research and build pathways for potential future review; it does not waive FDA standards.
Federal-state research support
The order directs the Department of Health and Human Services (HHS), through the Advanced Research Projects Agency for Health (ARPA-H), to allocate at least $50 million from existing funds to support and partner with states that have enacted or are developing programs to advance psychedelic drugs for serious mental illness. This is a direction in the order for federal-state collaboration, not a statement that a new treatment has been funded or approved.
Clinical trials and possible rescheduling
HHS and the FDA are directed to work with the Department of Veterans Affairs (VA) and, where appropriate, private-sector partners to increase participation in clinical trials, share data and generate real-world evidence. The order prioritizes drugs with FDA Breakthrough Therapy designation. It also directs the Attorney General, in consultation with HHS, to review qualifying Schedule I products after successful Phase 3 trials, so rescheduling can proceed quickly if a product is ultimately FDA-approved and rescheduling is appropriate under law. That conditional process does not itself change a drug’s legal status.
#1 Best Overall
- Read Before You Buy — No Video Output: These adapters support charging and USB 2.0 data transfer, but cannot transmit video signals. Except for standard USB webcams (which use USB data only), they are not compatible with HDMI/DisplayPort cables, video-capable USB-C hubs, or docking stations with video output.
- Convert USB-A Ports to USB-C: Designed to connect USB-C earphones, cables, flash drives, card readers, and other USB-C accessories to standard USB-A ports. Plug-and-play with no drivers or software required.
- Aluminum Alloy Housing: Built with a sturdy aluminum alloy shell that aids in heat dissipation and protects against daily wear and scratches. Designed to maintain a stable and secure connection.
- Compact & Travel-Friendly: The ultra-compact design allows the adapter to stay plugged into your device without blocking adjacent ports or adding bulk, reducing wear and tear on your original USB ports.
- 12-Month Warranty: Backed by a 12-month manufacturer warranty for peace of mind. Designed to meet strict quality control standards for reliable everyday performance.
What did the FDA announce after the order?
On April 24, the FDA announced national priority vouchers for three companies’ investigational psychedelic-drug programs. It also said a sponsor could begin an early-phase study of noribogaine hydrochloride after its Investigational New Drug submission. These are development steps, not evidence that the candidates have demonstrated benefit.
| Compound or program | Condition being studied | Development step announced |
|---|---|---|
| Psilocybin | Treatment-resistant depression | National priority voucher announced by FDA |
| Psilocybin | Major depressive disorder | National priority voucher announced by FDA |
| Methylone | Post-traumatic stress disorder (PTSD) | National priority voucher announced by FDA |
| Noribogaine hydrochloride | Alcohol use disorder | FDA allowed a sponsor to begin a Phase I study in a closely monitored U.S. clinical setting after an Investigational New Drug submission |
The FDA explicitly said that permission for the noribogaine study does not mean the drug is approved or has been found safe or effective. A study’s permission to proceed is not a treatment option for patients outside the study.
Rank #2
- 5-in-1 USB-C Hub: Experience comprehensive connectivity featuring a Power Delivery input, two USB-A 2.0 ports, a USB-A 3.0 port, and an HDMI port. (Note: The USB-C power delivery input port is only for connecting an external wall charger to power your laptop and cannot power peripheral devices.)
- 90W Pass-Through Charging: Achieve optimal charging with 90W pass-through power to your laptop, supported by a total input of 100W, with the hub reserving 10W for operational efficiency. (Note: Wall charger not included.)
- Quick Data Transfers: Accelerate your productivity with rapid data transfers using a high-speed 5Gbps USB 3.0 port and two 480Mbps USB 2.0 ports.
- 4K HDMI Display: Enhance your visual experience with a hub capable of delivering 4K resolution at 30Hz in both mirror and extend modes. Please note that this hub is compatible with MacBook (macOS 12 and newer), Windows 10 and 11, ChromeOS, and laptops equipped with DP Alt Mode and Power Delivery. Note: This device is not compatible with Linux.
- What You Get: Anker USB-C Hub (5-in-1, 4K HDMI), welcome guide, 18-month warranty, and our friendly customer service.
What does “MAHA-backed” mean here?
MAHA stands for “Make America Healthy Again,” the Trump administration’s health agenda associated with HHS Secretary Robert F. Kennedy Jr. Kennedy publicly described the administration’s April actions as accelerating research, approval and responsible access to promising mental-health treatments, especially for veterans. In the FDA’s April 24 announcement, he said the goal was to confront the mental-health crisis with treatments including psychedelic therapies like ibogaine.
However, Executive Order 14401 is framed around serious mental illness and does not identify itself as a MAHA Commission action. The available official descriptions support calling this an administration initiative associated with the broader MAHA agenda, not a formally named MAHA Commission program. The Commission’s specific role in originating or designing the order is not established.
Rank #3
- Sleek 7-in-1 USB-C Hub: Features an HDMI port, two USB-A 3.0 ports, and a USB-C data port, each providing 5Gbps transfer speeds. It also includes a USB-C PD input port for charging up to 100W and dual SD and TF card slots, all in a compact design.
- Flawless 4K@60Hz Video with HDMI: Delivers exceptional clarity and smoothness with its 4K@60Hz HDMI port, making it ideal for high-definition presentations and entertainment. (Note: Only the HDMI port supports video projection; the USB-C port is for data transfer only.)
- Double Up on Efficiency: The two USB-A 3.0 ports and a USB-C port support a fast 5Gbps data rate, significantly boosting your transfer speeds and improving productivity.
- Fast and Reliable 85W Charging: Offers high-capacity, speedy charging for laptops up to 85W, so you spend less time tethered to an outlet and more time being productive.
- What You Get: Anker USB-C Hub (7-in-1), welcome guide, 18-month warranty, and our friendly customer service.
How are veterans and care delivery part of the plan?
On July 13, 2026, HHS and VA announced a five-year memorandum of understanding to coordinate research, clinical development and preparation for responsible deployment of potential future rapid-acting treatments if they receive FDA approval.
- Increase veterans’ participation in clinical research.
- Train clinicians and develop clinical guidance.
- Collect and share real-world data on safety, effectiveness and costs.
Separately, the Health Resources and Services Administration (HRSA) sought public input on training and care-delivery models for possible future FDA-approved psychedelic therapies in ambulatory settings, including health centers and rural health clinics. That planning concerns how care might be delivered if products are approved; it is not evidence that such products are currently authorized for those settings.
Rank #4
- Dual Converters, Infinite Potential：Includes 2× USB C male to USB A female adapters and 2× USB A male to USB C female adapters. Perfect for a wide range of uses—tablets with Bluetooth keyboards, expand USB ports on macbook, and more. Two different converters for all your daily needs
- Next-Level 10Gbps & 3A Charging: No more slow 480Mbps, this usb to usb c adapter has a transfer speed of up to 10Gbps, allowing you to do more transferring in less time. This usb adapter fits both USB A and USB C charger, supporting up to 3A fast charging
- Upgraded Exquisite Craftsmanship: With an aluminum alloy housing and metal connector, the usbc to usb adapter is extremely durable and sturdy. Rigorously tested to withstand more than 10,000 times of plugging and unplugging, ensuring long-lasting performance
- Broad Compatible: The usb c to usb adapter widely supports all USB C/ USB A devices like laptops, tablets, cellphones, car chargers, and phone chargers. Such as compatible with MacBook Pro/Air 2023/2022, Thunderbolt 4/3 Devices,Apple MagSafe Watch 9/8/7/SE/Ultra, iPad Pro 2022/2021, Samsung Galaxy S23/S20/S10, and iPhone 17/16/15 Pro. Plug and play
- Please Note: To reach 10Gbps speed, keep the cable under 3.3 ft. For USB A Male to USB C adapters, try flipping the USB C connector. USB C Male to USB A adapters support bidirectional 10Gbps transfer within 3.3 ft
What has the FDA said about evidence and safety?
In July 2026, the FDA finalized its industry guidance, “Psychedelic Drugs: Considerations for Clinical Investigations.” It gives sponsors general recommendations on trial design, data collection, patient monitoring and conducting adequate, well-controlled clinical investigations. Guidance helps shape how studies are conducted; it is not a finding that a specific drug is safe or effective.
The FDA also held a public hearing on September 14, 2026, about potential future therapeutic use of psychedelic drug products in supervised and supportive settings. Written comments are due October 5, 2026. The hearing addresses possible therapies and care delivery broadly; it does not settle the evidence for any individual candidate.
Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minutePC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Best Value
- 5-in-1 Connectivity: Equipped with a 4K HDMI port, a 5 Gbps USB-C data port, two 5 Gbps USB-A ports, and a USB C 100W PD-IN port. Note: The USB C 100W PD-IN port supports only charging and does not support data transfer devices such as headphones or speakers.
- Powerful Pass-Through Charging: Supports up to 85W pass-through charging so you can power up your laptop while you use the hub. Note: Pass-through charging requires a charger (not included). Note: To achieve full power for iPad, we recommend using a 45W wall charger.
- Transfer Files in Seconds: Move files to and from your laptop at speeds of up to 5 Gbps via the USB-C and USB-A data ports. Note: The USB C 5Gbps Data port does not support video output.
- HD Display: Connect to the HDMI port to stream or mirror content to an external monitor in resolutions of up to 4K@30Hz. Note: The USB-C ports do not support video output.
- What You Get: Anker 332 USB-C Hub (5-in-1), welcome guide, our worry-free 18-month warranty, and friendly customer service.
For ibogaine-related compounds, Associated Press reporting in April 2026 described concerns about irregular heart rhythms and prior cardiovascular-toxicity concerns. Those are safety concerns reported in connection with ibogaine, not a conclusion issued by the executive order. The FDA’s specific statement on the noribogaine study remains that permission to proceed is not approval or a determination of safety or effectiveness.
What should readers take away?
This is a federal effort to accelerate investigation and prepare agencies and care systems for possible future treatments, with veterans an especially prominent intended population. The next meaningful clinical milestones are trial results and, if a sponsor seeks marketing authorization, FDA review under its standards. Until then, the programs in the April announcement are investigational development programs, not a menu of approved psychedelic treatments.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
